CN112754963A - 紧致抗皱护肤品的使用方法 - Google Patents
紧致抗皱护肤品的使用方法 Download PDFInfo
- Publication number
- CN112754963A CN112754963A CN202011642603.3A CN202011642603A CN112754963A CN 112754963 A CN112754963 A CN 112754963A CN 202011642603 A CN202011642603 A CN 202011642603A CN 112754963 A CN112754963 A CN 112754963A
- Authority
- CN
- China
- Prior art keywords
- active ingredient
- skin
- parts
- care product
- mass percentage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000006071 cream Substances 0.000 claims abstract description 37
- 230000003796 beauty Effects 0.000 claims abstract description 24
- 235000013336 milk Nutrition 0.000 claims abstract description 24
- 210000004080 milk Anatomy 0.000 claims abstract description 24
- 239000008267 milk Substances 0.000 claims abstract description 23
- 239000002537 cosmetic Substances 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 239000006210 lotion Substances 0.000 claims abstract description 13
- 239000000839 emulsion Substances 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims description 60
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 20
- -1 small-molecule sodium hyaluronate Chemical class 0.000 claims description 20
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 16
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 16
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 16
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 16
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 16
- 229960003237 betaine Drugs 0.000 claims description 16
- 229940036350 bisabolol Drugs 0.000 claims description 16
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 16
- 239000003974 emollient agent Substances 0.000 claims description 16
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 15
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 12
- 239000003906 humectant Substances 0.000 claims description 12
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 12
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 11
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 10
- 229960000458 allantoin Drugs 0.000 claims description 10
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- 229940042585 tocopherol acetate Drugs 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- SCVVSSZVLZQUDZ-UHFFFAOYSA-N 3-methyl-2,6-dihydro-1H-pyrimidine-2-carboxylic acid Chemical compound CN1C(NCC=C1)C(=O)O SCVVSSZVLZQUDZ-UHFFFAOYSA-N 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 5
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 229940057910 shea butter Drugs 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 4
- 229920002521 macromolecule Polymers 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- 241000209490 Nymphaea Species 0.000 claims description 3
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 claims description 3
- 210000001015 abdomen Anatomy 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 240000003538 Chamaemelum nobile Species 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 2
- 240000006908 Nymphaea odorata Species 0.000 claims description 2
- 235000006490 Nymphaea odorata Nutrition 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-M prolinate Chemical compound [O-]C(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-M 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 16
- 230000003020 moisturizing effect Effects 0.000 abstract description 13
- 230000037303 wrinkles Effects 0.000 abstract description 13
- 230000037394 skin elasticity Effects 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 4
- 230000007815 allergy Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 115
- 238000012360 testing method Methods 0.000 description 43
- 230000008859 change Effects 0.000 description 33
- 238000003756 stirring Methods 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 18
- 206010040954 Skin wrinkling Diseases 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 230000001804 emulsifying effect Effects 0.000 description 15
- 238000001816 cooling Methods 0.000 description 14
- 239000003995 emulsifying agent Substances 0.000 description 11
- 210000000434 stratum corneum Anatomy 0.000 description 10
- 239000002562 thickening agent Substances 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 9
- 230000002335 preservative effect Effects 0.000 description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 8
- 230000003712 anti-aging effect Effects 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 230000001815 facial effect Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 229960001631 carbomer Drugs 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 229960005323 phenoxyethanol Drugs 0.000 description 6
- 238000005191 phase separation Methods 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229940100524 ethylhexylglycerin Drugs 0.000 description 4
- 238000005562 fading Methods 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940031575 hydroxyethyl urea Drugs 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000037393 skin firmness Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 235000009967 Erodium cicutarium Nutrition 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940100554 isononyl isononanoate Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000037070 skin defense Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- PAEMERHSTIDLSE-VEIQOZLZSA-N (3r,4s,5s,6r)-2-hexadecoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PAEMERHSTIDLSE-VEIQOZLZSA-N 0.000 description 1
- XOAIXMQPJQVGRV-UHFFFAOYSA-N 1-hexadecanoylpyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N1CCCC1C(O)=O XOAIXMQPJQVGRV-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940087073 glycol palmitate Drugs 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229940104256 sodium taurate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8164—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/895—Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及化妆品技术领域,公开了一种紧致抗皱护肤品的使用方法,所述紧致抗皱护肤品包括美容液、精华乳及面霜,包括以下步骤:依次将美容液、精华乳及面霜涂抹于皮肤上;其中,美容液的使用质量百分含量为0.2~0.6%,精华乳的使用质量百分含量为0.1~0.3%,面霜的使用质量百分含量为0.3~1.0%;该美容液具有抗敏舒缓修复的功效,该精华乳具有密集补水保湿的功效,该面霜具有抗衰老抗皱的功效,三者在一定的使用比例下相互协同增效,可以明显增加肌肤滋润性,提升皮肤弹性,淡化细纹皱纹。
Description
技术领域
本发明涉及化妆品技术领域,特别是涉及一种紧致抗皱护肤品的使用方法。
背景技术
众所周知,肌肤老化分自然老化和环境因素导致的老化,一般25岁以后,女性的皮肤的新陈代谢就会日趋缓慢,角质层会渐渐堆积变厚。除了年龄会影响皮肤状况,由于工作、生活压力导致的体内荷尔蒙的变化,环境的污染,紫外线的辐射,不良的饮食习惯以及不恰当的肌肤保养方式均会影响皮肤健康,导致大量自由基的生成,这些活跃的分子基团会引发一系列自由基反应,造成细胞的损伤甚至死亡,从而使肌肤加速衰老。坚持长期正确使用有效的抗衰紧致护肤品,在一定程度上可以有效延缓皮肤衰老的速度。
目前,市场上宣称抗衰紧致的护肤品品类繁多、质量也良莠不齐,有的产品使用后不但起不到抗衰老的效果,反而带来刺激、瘙痒等肌肤问题,或导致敏感肌肤的出现,有的产品只能对25~35的初老皮肤起到抗衰老的效果,对于35~55岁的衰老皮肤却功效甚微。而且,使用方法不当,不仅无法良好发挥护肤品的功效,还可能引起过敏、闷痘、脂肪粒等。
发明内容
本发明的目的是克服现有技术中的不足之处,提供一种紧致抗皱护肤品的使用方法,可以明显增加肌肤滋润性,提升皮肤弹性,淡化细纹皱纹。
本发明的目的是通过以下技术方案来实现的:
一种紧致抗皱护肤品的使用方法,所述紧致抗皱护肤品包括美容液、精华乳及面霜,包括以下步骤:
依次将所述美容液、所述精华乳及所述面霜涂抹于皮肤上;
其中,所述美容液的使用质量百分含量为0.2~0.6%,所述精华乳的使用质量百分含量为0.1~0.3%,所述面霜的使用质量百分含量为0.3~1.0%;
所述美容液包括质量百分含量为6.83~15.6%的皮肤调理剂A;所述皮肤调理剂A包括尿囊素、甜菜碱、活性成分A1、活性成分B1、活性成分C1、二棕榈酰羟脯氨酸、活性成分D1、红没药醇及活性成分E1,所述活性成分A1包括β-葡聚糖及甘油,所述活性成分B1包括甘油聚丙烯酸酯及PVM/MA共聚物,所述活性成分C1包括木糖醇基葡糖苷、木糖醇、脱水木糖醇及葡萄糖,所述活性成分D1包括棕榈酰脯氨酸钠及白睡莲花提取物,所述活性成分E1包括母菊花提取物;
所述精华乳包括以下质量百分含量的组分:皮肤调理剂B 2.51~7.29%、保湿剂B4.1~8.3%及润肤剂B 8~18%;所述皮肤调理剂B包括小分子透明质酸钠、活性成分A2、尿囊素、甜菜碱、生育酚乙酸酯、红没药醇及烟酰胺,所述活性成分A2包括大分子透明质酸钠;所述保湿剂B包括甘油、丁二醇及乙基己基甘油;所述润肤剂B包括润肤成分A2、聚二甲基硅氧烷及矿油,所述润肤成分A2包括C12-15醇苯甲酸酯及C12-15醇;
所述面霜包括质量百分含量为16~29%的皮肤调理剂C;所述皮肤调理剂C包括透明质酸钠、氢化卵磷脂、四氢甲基嘧啶羧酸、水解胶原、甜菜碱、二棕榈酰羟脯氨酸、牛油果树果脂、生育酚乙酸酯、活性成分A3、活性成分B3、活性成分C3及红没药醇;所述活性成分A3包括聚二甲基硅氧烷、环五聚二甲基硅氧烷及聚甲基硅倍半氧烷其中至少一种,所述活性成分B3包括环五聚二甲基硅氧烷及聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物其中至少一种,所述活性成分C3包括棕榈酰脯氨酸钠及白睡莲提取物其中至少一种。
在其中一种实施方式,上述紧致抗皱护肤品的使用方法具体包括以下步骤:
(1)将所述美容液均匀涂抹于皮肤上,轻拍至吸收;
(2)再将所述精华乳均匀涂抹于皮肤上,轻拍至吸收;
(3)再将所述面霜于双手指腹温热后,均匀涂抹于皮肤上。
在其中一种实施方式,所述步骤(3)中温热时间为1~30秒。优选地,所述步骤(3)中温热时间为3~15秒。优选地,所述步骤(3)中温热时间为3~10秒。更优选地,所述步骤(3)中温热时间为3~5秒。
优选地,所述美容液的使用质量百分含量为0.2~0.4%,所述精华乳的使用质量百分含量为0.1~0.2%,所述面霜的使用质量百分含量为0.4~0.6%。
优选地,所述美容液的使用质量百分含量为0.2%,所述精华乳的使用质量百分含量为0.1%,所述面霜的使用质量百分含量为0.4%。
优选地,所述美容液的使用质量百分含量为0.4%,所述精华乳的使用质量百分含量为0.2%,所述面霜的使用质量百分含量为0.6%。
优选地,所述美容液的使用质量百分含量为0.3%,所述精华乳的使用质量百分含量为0.15%,所述面霜的使用质量百分含量为0.48%。
在美容液中:
优选地,所述皮肤调理剂A包括以下质量份数的组分:尿囊素0.02~0.2份、甜菜碱0.3~0.7份、活性成分A1 3~7份、活性成分B1 2~4份、活性成分C1 0.6~1份、二棕榈酰羟脯氨酸0.01~0.1份、活性成分D1 0.4~1份、红没药醇0.01~0.1份及活性成分E1 0.5~1.5份。
在其中一种实施方式,所述美容液还包括质量百分含量为3~7.5%的保湿剂A,所述保湿剂A包括1.3丙二醇及乙基己基甘油其中至少一种。优选地,所述保湿剂A包括以下质量份数的组分:1.3丙二醇3~7份及乙基己基甘油0.1~0.3份。
在其中一种实施方式,所述美容液还包括质量百分含量为2~6%的润肤剂A,所述润肤剂A包括异壬酸异壬酯及环五聚二甲基硅氧烷其中至少一种。优选地,所述润肤剂A包括以下质量份数的组分:异壬酸异壬酯1~2份及环五聚二甲基硅氧烷1~4份。
在其中一种实施方式,所述美容液还包括以下质量百分含量的组分:增稠剂A0.15~0.45%、螯合剂A 0.03~0.07%、乳化剂A 0.6~1%及PH调节剂A0.1~0.3%。
优选地,所述增稠剂A包括卡波姆及丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物其中至少一种。优选地,所述增稠剂A包括以下质量份数的组分:卡波姆0.1~0.3份及丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物0.05~0.15份。
优选地,所述螯合剂A为EDTA-二钠。
优选地,所述乳化剂A为甘油硬脂酸酯柠檬酸酯,是经过Ecocert认证的有机天然植物乳化剂,是一款化妆品食品兼用的乳化剂,其温和性和安全性是完全有保障的,可专用于敏感肌肤及孕婴产品,相比于其他乳化剂,对皮肤更温和。
优选地,所述PH调节剂A为三乙醇胺。
在其中一种实施方式,所述美容液还包括质量百分含量为0~1%的防腐剂A,所述防腐剂A包括羟苯甲酯及苯氧乙醇其中至少一种。优选地,所述防腐剂A包括以下质量份数的组分:羟苯甲酯0~0.3份及苯氧乙醇0~0.7份。
在其中一种实施方式,所述美容液还包括质量百分含量为0~0.1%的香精A。
在精华乳中:
优选地,所述皮肤调理剂B包括以下质量份数的组分:小分子透明质酸钠0.03~0.07份、活性成分A2 0.03~0.07份、尿囊素0.1~0.3份、甜菜碱1~3份、生育酚乙酸酯0.3~0.7份、红没药醇0.05~0.15份及烟酰胺1~3份。
优选地,所述小分子透明质酸钠的分子量为50万~80万,所述大分子透明质酸钠的分子量为130万~150万。
优选地,所述保湿剂B包括以下质量份数的组分:甘油2~4份、丁二醇2~4份及乙基己基甘油0.1~0.3份。
优选地,所述润肤剂B包括以下质量份数的组分:润肤成分A2 3~7份、聚二甲基硅氧烷2~4份及矿油3~7份。
在其中一种实施方式,所述精华乳还包括以下质量百分含量的组分:增稠剂B0.65~1.35%、螯合剂B 0.03~0.07%、乳化剂B 8.8~14.2%、抗氧化剂B 0~0.04%及PH调节剂B 0.06~0.16%。
优选地,所述增稠剂B包括卡波姆、黄原胶及丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物其中至少一种。优选地,所述增稠剂B包括以下质量份数的组分:卡波姆0.1~0.2份、黄原胶0.05~0.15份及丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物0.6~1份。
优选地,所述乳化剂B包括乳化成分A2、甘油硬脂酸酯及鲸蜡醇乙基己酸酯其中至少一种,所述乳化成分A2包括甘油硬脂酸酯及PEG-100硬脂酸酯其中至少一种。优选地,所述乳化剂B包括以下质量份数的组分:乳化成分A20.5~1.5份、甘油硬脂酸酯0.3~0.7份及鲸蜡醇乙基己酸酯8~12份。
优选地,所述螯合剂B为EDTA-二钠。
优选地,所述抗氧化剂B为丁羟甲苯。
优选地,所述PH调节剂B为三乙醇胺。
在其中一种实施方式,所述精华乳还包括质量百分含量为0~1.2%的防腐剂B,所述防腐剂B包括羟苯甲酯、羟苯丙酯及苯氧乙醇其中至少一种。优选地,所述防腐剂B包括以下质量份数的组分:羟苯甲酯0~0.3份、羟苯丙酯0~0.2份及苯氧乙醇0~0.7份。
在其中一种实施方式,所述精华乳还包括质量百分含量为0~0.1%的香精B。
在面霜中:
优选地,所述皮肤调理剂C包括以下质量份数的组分:透明质酸钠0.03~0.07份、氢化卵磷脂0.6~1份、四氢甲基嘧啶羧酸0.05~0.15份、水解胶原0.3~0.7份、甜菜碱2~4份、二棕榈酰羟脯氨酸0.3~0.7份、牛油果树果脂6~10份、生育酚乙酸酯0.3~0.7份、活性成分A3 3~5份、活性成分B3 3~5份、活性成分C3 0.5~1.5份及红没药醇0.03~0.07份。
在其中一种实施方式,所述面霜还包括质量百分含量为10~18.3%的保湿剂C,所述保湿剂C包括丙二醇、甘油、羟乙基脲及乙基己基甘油其中至少一种。优选地,所述保湿剂C包括以下质量份数的组分:丙二醇4~8份、甘油4~6份、羟乙基脲2~4份及乙基己基甘油0.1~0.3份。
在其中一种实施方式,所述面霜还包括质量百分含量为5.5~10.5%的润肤剂C,所述润肤剂C包括氢化聚异丁烯、聚二甲基硅氧烷及环五聚二甲基硅氧其中至少一种。优选地,所述润肤剂C包括以下质量份数的组分:氢化聚异丁烯3~5份、聚二甲基硅氧烷0.5~1.5份及环五聚二甲基硅氧烷2~4份。
在其中一种实施方式,所述面霜还包括以下质量百分含量的组分:增稠剂C0.15~0.35%、螯合剂C 0.03~0.07%、乳化剂C 6.3~12.5%、抗氧化剂C 0~0.07%及PH调节剂C 0.05~0.15%。
优选地,所述乳化剂C包括乳化成分A3、鲸蜡硬酯醇、乙二醇棕榈酸酯、甘油硬脂酸酯及聚甘油-10肉豆蔻酸酯其中至少一种,所述乳化成分A3包括鲸蜡硬酯醇及鲸蜡硬酯基葡糖苷其中至少一种。优选地,所述乳化剂C包括以下质量份数的组分:乳化成分A3 2~4份、鲸蜡硬酯醇1.2~3.2份、乙二醇棕榈酸酯2~3份、甘油硬脂酸酯1~2份及聚甘油-10肉豆蔻酸酯0.1~0.3份。
优选地,所述增稠剂C包括卡波姆及黄原胶其中至少一种。优选地,所述增稠剂C包括以下质量份数的组分:卡波姆0.1~0.2份及黄原胶0.05~0.15份。
优选地,所述螯合剂C为EDTA-二钠。
优选地,所述抗氧化剂C为丁羟甲苯。
优选地,所述PH调节剂C为三乙醇胺。
在其中一种实施方式,所述面霜还包括质量百分含量为0~1.6%的防腐剂C,所述防腐剂C包括羟苯甲酯、羟苯丙酯及苯氧乙醇其中至少一种。优选地,所述防腐剂C包括以下质量份数的组分:羟苯甲酯0~0.2份、羟苯丙酯0~0.7份及苯氧乙醇0~0.7份。
在其中一种实施方式,所述面霜还包括质量百分含量为0~0.1%的香精C。
与现有技术相比,本发明至少具有以下优点:
1、该美容液具有抗敏舒缓修复的功效,该精华乳具有密集补水保湿的功效,该面霜具有抗衰老抗皱的功效,三者在一定的使用比例下相互协同增效,可以明显增加肌肤滋润性,提升皮肤弹性,淡化细纹皱纹。
2、本发明提供的美容液选用了尿囊素、甜菜碱、红没药醇及活性成分A~E,在特定的比例范围内,可以发挥出活性成分的超强搭配作用,具有瞬时补水保湿功效,能高效镇定皮肤,即刻缓解皮肤过敏产生的干燥紧绷、瘙痒红肿等现象;并且可以构建肌肤防御堡垒,强健肌底,使用一定时间后,对35~55岁衰老皮肤的过敏皮肤可以起到显著的抗敏舒缓修复功效。
3、本发明提供的精华乳选用了特定组分的皮肤调理剂、保湿剂及润肤剂,在特定的比例范围内,三者可以发挥出相互协同的增效作用,能快速被衰老皮肤吸收而立刻发挥作用,对35~55岁的衰老皮肤可以起到显著的瞬时补水保湿的功效;其主要的保湿机理:(1)防止水分蒸发的油脂保湿:润肤成分A、聚二甲基硅氧烷、矿油等,在皮肤上通过油脂形成保湿屏障,使皮肤的水分不易蒸发散失,也保护皮肤不受外界污染物的入侵;(2)吸收外界水分的吸湿保湿:甘油、丁二醇、乙基己基甘油等,具有自周围环境中吸取水分的功能,补水的同时也可将水分牢牢锁住,长久滋润肌肤;(3)结合水合作用的水合保湿:小分子透明质酸钠、大分子透明质酸钠等,会与水相融形成一个网状结构,将自由自在的游离水结合在它的网内,使自由水变成结合水而不易蒸发散失,达到长效保湿效果。(4)修复角质细胞的修复保湿:尿囊素、生育酚乙酸酯、甜菜碱、红没药醇、烟酰胺等,通过渗入皮肤的表皮甚至真皮内,经过生物作用,最终对角质层的吸水能力合屏障功能起到修护和加强作用,维持皮肤角质层的含水量,能够从根源解决皮肤缺水问题;同时还有舒缓抗敏的作用,可以降低皮肤炎症,减轻皮肤粉刺,防止暗疮产生,提高皮肤的抗刺激能力,修复有炎症受伤的皮肤。
4、本发明提供的面霜通过牛油果树果脂、氢化卵磷脂等油脂类成分,丙二醇、甘油、羟乙基脲等吸湿性成分,透明质酸钠、水解胶原等亲水性成分,及甜菜碱、生育酚乙酸酯、活性成分C、红没药醇等修复性成分之间的相互协同的增效作用,能多方面呵护皮肤,强效密集补水保湿,对35~55岁的衰老皮肤可以起到显著的瞬时补水保湿的功效;同时构建肌肤防御堡垒,强健肌底;再通过四氢甲基嘧啶羧酸、二棕榈酰羟脯氨酸等强效的抗衰老成分,复配活性成分A及活性成分B,通过活性成分A及活性成分B的抗紫外线作用,来抵御由紫外线引起的皮肤衰老,从而增效抗皱抗衰老的功能,能多维抗老,重拾弹力改善皮肤松弛;同时起到增稠作用,可以起到减少增稠剂用量的作用,而且质地比油脂类成分更清爽轻薄,可以降低精华霜的油腻感;后通过棕榈酰脯氨酸钠及白睡莲提取物可以减少由于炎症(紫外线、刺激、粉刺)和衰老引起的色素沉着,起到美白祛斑的功效;并且复配甜菜碱、生育酚乙酸酯、红没药醇等成分,还可以帮助皮肤抵抗外界刺激,缓解热敏引起的疼痛,降低表皮温度,达到抗过敏舒缓的效果,有效修复皮肤敏感或皮肤炎症。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,应当理解,以下附图仅示出了本发明的某些实施例,因此不应被看作是对范围的限定,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他相关的附图。
图1为实施例1两名受试者在不同的时间点眼下区域细纹的变化。
图2为实施例1一名受试者在不同的时间点脸颊细纹的变化。
图3为实施例1两名受试者在不同的时间点鱼尾纹的变化。
图4为受试者在使用实施例1后自我评价(满意度)。
图5为受试者在使用实施例1后的自我评价(百分比)。
具体实施方式
需要说明的是,本发明可以以许多不同的形式来实现,并不限于本文所描述的实施方式。相反地,提供这些实施方式的目的是使对本发明的公开内容理解的更加透彻全面。
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施方式的目的,不是旨在于限制本发明。本文所使用的术语“及/或”包括一个或多个相关的所列项目的任意的和所有的组合。
实施例1~4的紧致抗皱护肤品分别包括实施例1~4的美容液、实施例1~4的精华乳及实施例1~4的面霜。
实施例1~4的美容液,包括质量百分含量为如表1所示组分。
表1.实施例1~4的美容液组分表
将表1中的配方按照以下步骤进行制备
1:将A分相加入乳化锅中,以20~40r/min搅拌,再将提前混合好的A1分相加入乳化锅中,升温至80~85度,保温15~25min,再以20~40HZ频率均质2~4min,再加入A2分相,搅拌降温并抽真空3~5min;
2:将B分相于铁锅中用电磁炉于80~90度溶解完全,乳化前1~3min加入B1分相,搅拌均匀;
3:将步骤2得到的混合物加入乳化锅中,以30~40HZ的频率均质2~4min,搅拌均匀;
4:将步骤3得到的混合物以20~40r/min速度真空搅拌降温到65~70度,加入E分相;
5:将步骤4得到的混合物以20~40r/min速度降温到55~60度,加入D分相和H分相,搅拌均匀;
6:将步骤5得到的混合物以20~40r/min速度降温到45~50度,加入F分相,搅拌均匀;
7:将步骤6得到的混合物以20~40r/min速度继续搅拌降温到35~40度,加入G分相,搅拌均匀;
8:待品控检验合格后,出料。
实施例1~4的精华乳,包括质量百分含量为如表2所示组分。
表2.实施例1~4的精华乳组分表
将表2中的配方按照以下步骤进行制备:
1:将A分相加入乳化锅中,以20~40r/min搅拌,再将提前分别混合好的A1分相和A2分相加入乳化锅中,升温至80~85度,保温15~25min,再以20~40HZ频率均质2~4min,再加入A3分相,搅拌降温并抽真空3~5min;
2:将B分相于油锅中80~90度溶解完全,乳化前1~3min加入B1分相,搅拌均匀;
3:将步骤2得到的混合物加入乳化锅中,以30~40HZ的频率均质2~4min,搅拌均匀;
4:将步骤3得到的混合物以20~40r/min速度真空搅拌降温到65~70度,加入C分相和提前混合好的C1分相,搅拌均匀;
5:将步骤4得到的混合物以20~40r/min速度降温到55~60度,加入提前混合好的C2分相,以25~35HZ的频率均质2~4min,搅拌均匀;
6:将步骤5得到的混合物以20~40r/min速度降温到45~50度,加入D分相和E分相,搅拌均匀;
7:将步骤6得到的混合物以20~40r/min速度继续搅拌降温到35~40度,加入F分相,搅拌均匀;
8:待品控检验合格后,出料。
实施例1~4的面霜,包括质量百分含量为如表3所示组分。
表3.实施例1~4的面霜组分表
将表3中的配方按照以下步骤进行制备:
1:将A分相加入乳化锅中,以20~40r/min搅拌,再将提前分别混合好的A1分相和A3分相加入乳化锅中,升温至80~85度,保温15~25min,再以20~40HZ频率均质2~4min,再加入A2分相,搅拌降温并抽真空3~5min;
2:将B分相于油锅中80~90度溶解完全,乳化前1~3min加入B1分相,均质1~3min,搅拌均匀;
3:将步骤2得到的混合物加入乳化锅中,以30~40HZ的频率均质2~4min,搅拌均匀;
4:将步骤3得到的混合物以20~40r/min速度真空搅拌降温到65~70度,加入C分相,搅拌均匀;
5:将步骤4得到的混合物以20~40r/min速度降温到45~50度,加入D分相、E分相和F分相,搅拌均匀;
6:将步骤5得到的混合物以20~40r/min速度继续搅拌降温到35~40度,加入G分相,搅拌均匀;
7:待品控检验合格后,出料。
实施例1~4的紧致抗皱护肤品,包括使用量为如表4所示组分。
表4.实施例1~4组分表
将表4的组分配比按照以下步骤进行使用:
(1)将所述美容液均匀涂抹于面部皮肤上,轻拍至吸收;
(2)再将所述精华乳均匀涂抹于面部皮肤上,轻拍至吸收;
(3)再将所述面霜于双手指腹温热1~30秒后,均匀涂抹于面部皮肤上。
对比例1
将市售的百雀羚肌初水、肌初精华乳和肌初霜三件套产品,按照实施例1的使用方法进行使用。
测试实验:1、皮肤含水量测试—补水保湿。
受试者要求:年龄35~55岁健康女性;肤色暗沉,无光泽,皮肤松弛下垂,失去弹性;皮肤粗糙干燥,皱纹明显。按照测试品的种类分组。n代表每组人数。
数据统计:数据使用SPSS进行统计,对测试数据进行正态分布检验,若测试数据为正态分布,则采用t检验方法进行统计分析;若测试数据为非正态分布,则采用秩和检验方法进行统计分析,统计方法均采用双尾检验,检验水准α=0.05。
测试方法:左右脸随机对照,双盲测试;分别取约珍珠大小的实施例1~4及对比例1的测试品于双手指腹温热数秒,均匀涂抹于面部,然后采用皮肤水分测试仪(德国CKCorneometer CM 825)在使用前、2周、4周面部测试区域的皮肤含水量,实施例1及对比例1的测试结果如表5所示。实施例2~4的测试结果与实施例1的测试结果相近,实施例1的皮肤含水量的增加率最高,为最佳实施例。
表5受试者在不同的时间点面部测试区域角质层水分含量变化
皮肤水分测定仪Corneometer CM 825用于检测皮肤角质层水分含量,皮肤角质层水分含量测量值越高,说明皮肤角质层水分含量越高。
由表5数据可见,使用实施例1的测试品在使用2周、使用4周面部皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异,均具有统计学意义(P<0.05),整体皮肤含水量成上升趋势。对比例1在使用2周面部皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异,不具有统计学意义(P>0.05),对比例1在使用4周面部皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异,具有统计学意义(P<0.05)。同时,实施例1和对比例1两组的测定值与初始值的差值在使用2周进行比较,数据不具有显著性差异(P>0.05),实施例1和对比例1两组的测定值与初始值的差值在使用4周进行比较,数据具有显著性差异(P<0.05)。实验数据表明,实施例1在使用4周后的测定值与初始值的差值与对比例1相比,有显著提高,补水效果更显著。也就是说,本发明提供的紧致抗皱护肤品比某市售产品更具有长期提高皮肤含水量的作用。
表5数据表明,相比于对比例1,本发明提供的紧致抗皱护肤品能够明显提高衰老皮肤角质层水分含量,对衰老皮肤的补水保湿的效果更显著。
2、皮肤弹性测试。
采用皮肤弹性测试仪(Cutometer dual MPA580)检测皮肤的弹性。实施例1及对比例1的测试结果如表6所示。实施例2~4的测试结果与实施例1的测试结果相近,实施例1的R2值的增加率最高,为最佳实施例。
表6受试者在不同的时间点面部测试区域R2值的变化
经皮肤弹性测试仪(Cutometer dual MPA580)检测皮肤的弹性,R2值越高(趋于100),说明皮肤的弹性越好。
由表6数据可见,使用实施例1的测试品在使用2周面部弹性R2变化值与使用前面部弹性R2变化值的数据差异,不具有统计学意义(P>0.05);使用实施例1的测试品在使用4周面部弹性R2变化值与使用前面部弹性R2变化值的数据差异,具有统计学意义(P<0.05)。对比例1在使用2周、使用4周面部弹性R2变化值与使用前面部弹性R2变化值的数据差异,不具有统计学意义(P>0.05)。同时,实施例1和对比例1两组的测定值与初始值的差值在使用2周、使用4周进行比较,数据具有显著性差异(P<0.05)。
表6数据表明,相比于对比例1,本发明提供的紧致抗皱护肤品能够明显提高皮肤R2值,提升皮肤弹性的效果更显著。
3、面部图像分析—淡化细纹。
3.1眼下细纹测试。
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件,选取受试者眼睛下方进行眼下细纹面积计算。实施例1及对比例1的测试结果如表7所示。实施例2~4的测试结果与实施例1的测试结果相近,实施例1的眼下细纹面积的减少率最高,为最佳实施例。
图1为实施例1两名受试者在不同的时间点眼下区域细纹的变化。
表7受试者在不同的时间点眼下细纹面积变化
由表7数据可见,使用实施例1的测试品在使用2周面部眼下细纹面积的变化值与使用前眼下细纹面积变化值的数据差异,不具有统计学意义(P>0.05);使用实施例1的测试品在使用4周眼下细纹面积变化值与使用前眼下细纹面积变化值的数据差异,具有统计学意义(P<0.05)。对比例1在使用2周、使用4周眼下细纹面积变化值与使用前眼下细纹面积变化值的数据差异,不具有统计学意义(P>0.05)。同时,实施例1和对比例1两组的测定值与初始值的差值在使用2周、使用4周进行比较,数据具有显著性差异(P<0.05)。
表7数据表明,相比于对比例1,本发明提供的紧致抗皱护肤品能够明显减少衰老皮肤的眼下细纹面积,对眼下细纹的淡化效果更显著。同时从图1可看出,在使用28天后,实施例1受试者的眼下细纹明显减少,皮肤更加平整,可见本发明提供的紧致抗皱护肤品在正确使用一定时间后能够显著改善衰老皮肤的眼下细纹问题。
3.2脸颊细纹测试。
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件,选取受试者左右脸颊进行脸颊细纹面积的计算。实施例1及对比例1的测试结果如表8所示。实施例2~4的测试结果与实施例1的测试结果相近,实施例1的脸颊细纹面积的减少率最高,为最佳实施例。
图2为实施例1一名受试者在不同的时间点脸颊细纹的变化。
表8受试者在不同的时间点脸颊细纹面积变化
由表8数据可见,使用实施例1的测试品在使用2周脸颊细纹面积的变化值与使用前脸颊细纹面积变化值的数据差异,不具有统计学意义(P>0.05);使用实施例1的测试品在使用4周脸颊细纹面积变化值与使用前脸颊细纹面积变化值的数据差异,具有统计学意义(P<0.05)。对比例1在使用2周脸颊细纹面积变化值与使用前脸颊细纹面积变化值的数据差异,不具有统计学意义(P>0.05)。对比例1在使用4周脸颊细纹面积变化值与使用前脸颊细纹面积变化值的数据差异,具有统计学意义(P<0.05)。同时,实施例1和对比例1两组的测定值与初始值的差值在使用2周进行比较,数据不具有显著性差异(P>0.05)。实施例1和对比例1两组的测定值与初始值的差值在使用4周进行比较,数据具有显著性差异(P<0.05)。
表8数据表明,相比于对比例1,本发明提供的紧致抗皱护肤品能够明显减少衰老皮肤的脸颊细纹面积,对脸颊细纹的淡化效果更显著。同时从图2可看出,在使用28天后,实施例1受试者的脸颊细纹明显减少,皮肤更加平整,可见本发明提供的紧致抗皱护肤品在正确使用一定时间后能够显著改善衰老皮肤的脸颊细纹问题。
3.3鱼尾纹测试。
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件,选取受试者眼角进行鱼尾纹面积计算。实施例1及对比例1的测试结果如表9所示。实施例2~4的测试结果与实施例1的测试结果相近,实施例1的鱼尾纹面积的减少率最高,为最佳实施例。
图3为实施例1两名受试者在不同的时间点鱼尾纹的变化。
表9受试者在不同的时间点鱼尾纹面积变化
由表9数据可见,使用实施例1的测试品在使用2周鱼尾纹面积的变化值与使用前鱼尾纹面积变化值的数据差异,不具有统计学意义(P>0.05);使用实施例1的测试品在使用4周鱼尾纹面积变化值与使用前鱼尾纹面积变化值的数据差异,具有统计学意义(P<0.05)。对比例1在使用2周、使用4周鱼尾纹面积变化值与使用前鱼尾纹面积变化值的数据差异,都不具有统计学意义(P>0.05)。同时,实施例1和对比例1两组的测定值与初始值的差值在使用2周、使用4周进行比较,数据具有显著性差异(P<0.05)。
表9数据表明,相比于对比例1,本发明提供的紧致抗皱护肤品能够明显减少衰老皮肤的鱼尾纹面积,对鱼尾纹的淡化效果更显著。同时从图3可看出,在使用28天后,实施例1受试者的鱼尾纹明显减少,皮肤更加平整,可见本发明提供的紧致抗皱护肤品在正确使用一定时间后能够显著改善衰老皮肤的鱼尾纹问题。
4、受试者自我评价。
对所有使用实施例1的受试者进行问卷调查,问卷调查是受试者对使用实施例1的测试品的主观评价,主要评价项目有:产品质地、产品香味、产品肤感、肌肤紧致度、肌肤弹性、肌肤光泽度、肌肤光滑度、肌肤滋润性及面部细纹,具体满意度见图4,具体百分比见图5。
满意度分析:由图4可见,92%的受试者认为使用产品面部皱纹有改善;受试者对产品的质地、香味、肤感的满意度为100%,100%的受试者认为使用产品4周后肌肤紧致度有提升,肌肤更有弹性、肌肤更加滋润、肌肤更有光泽和更光滑。
百分比分析:由图5可见,受试者认为使用产品4周后肌肤滋润增加了83%;皮肤紧致度提升了77%;皮肤弹性提升了75%;肌肤光滑改善了80%,肌肤光泽度提升了75%;面部皱纹改善了75%。
实施例2~4的测试品的功效评价结果与实施例1结果相近,不再赘述。
皮肤不良方应:使用测试品期间,0例受试者出现局部红斑、丘疹、风团、水肿或全身的皮肤不良方应。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种紧致抗皱护肤品的使用方法,所述紧致抗皱护肤品包括美容液、精华乳及面霜,其特征在于,包括以下步骤:
依次将所述美容液、所述精华乳及所述面霜涂抹于皮肤上;
其中,所述美容液的使用质量百分含量为0.2~0.6%,所述精华乳的使用质量百分含量为0.1~0.3%,所述面霜的使用质量百分含量为0.3~1.0%;
所述美容液包括质量百分含量为6.83~15.6%的皮肤调理剂A;所述皮肤调理剂A包括尿囊素、甜菜碱、活性成分A1、活性成分B1、活性成分C1、二棕榈酰羟脯氨酸、活性成分D1、红没药醇及活性成分E1,所述活性成分A1包括β-葡聚糖及甘油,所述活性成分B1包括甘油聚丙烯酸酯及PVM/MA共聚物,所述活性成分C1包括木糖醇基葡糖苷、木糖醇、脱水木糖醇及葡萄糖,所述活性成分D1包括棕榈酰脯氨酸钠及白睡莲花提取物,所述活性成分E1包括母菊花提取物;
所述精华乳包括以下质量百分含量的组分:皮肤调理剂B 2.51~7.29%、保湿剂B 4.1~8.3%及润肤剂B 8~18%;所述皮肤调理剂B包括小分子透明质酸钠、活性成分A2、尿囊素、甜菜碱、生育酚乙酸酯、红没药醇及烟酰胺,所述活性成分A2包括大分子透明质酸钠;所述保湿剂B包括甘油、丁二醇及乙基己基甘油;所述润肤剂B包括润肤成分A2、聚二甲基硅氧烷及矿油,所述润肤成分A2包括C12-15醇苯甲酸酯及C12-15醇;
所述面霜包括质量百分含量为16~29%的皮肤调理剂C;所述皮肤调理剂C包括透明质酸钠、氢化卵磷脂、四氢甲基嘧啶羧酸、水解胶原、甜菜碱、二棕榈酰羟脯氨酸、牛油果树果脂、生育酚乙酸酯、活性成分A3、活性成分B3、活性成分C3及红没药醇;所述活性成分A3包括聚二甲基硅氧烷、环五聚二甲基硅氧烷及聚甲基硅倍半氧烷其中至少一种,所述活性成分B3包括环五聚二甲基硅氧烷及聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物其中至少一种,所述活性成分C3包括棕榈酰脯氨酸钠及白睡莲提取物其中至少一种。
2.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,具体包括以下步骤:
(1)将所述美容液均匀涂抹于皮肤上,轻拍至吸收;
(2)再将所述精华乳均匀涂抹于皮肤上,轻拍至吸收;
(3)再将所述面霜于双手指腹温热后,均匀涂抹于皮肤上。
3.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述步骤(3)中温热时间为1~30秒。
4.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述美容液的使用质量百分含量为0.2~0.4%,所述精华乳的使用质量百分含量为0.1~0.2%,所述面霜的使用质量百分含量为0.4~0.6%。
5.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述美容液的使用质量百分含量为0.2%,所述精华乳的使用质量百分含量为0.1%,所述面霜的使用质量百分含量为0.4%。
6.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述美容液的使用质量百分含量为0.4%,所述精华乳的使用质量百分含量为0.2%,所述面霜的使用质量百分含量为0.6%。
7.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述美容液的使用质量百分含量为0.3%,所述精华乳的使用质量百分含量为0.15%,所述面霜的使用质量百分含量为0.48%。
8.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述皮肤调理剂A包括以下质量份数的组分:尿囊素0.02~0.2份、甜菜碱0.3~0.7份、活性成分A1 3~7份、活性成分B1 2~4份、活性成分C1 0.6~1份、二棕榈酰羟脯氨酸0.01~0.1份、活性成分D10.4~1份、红没药醇0.01~0.1份及活性成分E1 0.5~1.5份。
9.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述皮肤调理剂B包括以下质量份数的组分:小分子透明质酸钠0.03~0.07份、活性成分A2 0.03~0.07份、尿囊素0.1~0.3份、甜菜碱1~3份、生育酚乙酸酯0.3~0.7份、红没药醇0.05~0.15份及烟酰胺1~3份。
10.根据权利要求1所述的紧致抗皱护肤品的使用方法,其特征在于,所述皮肤调理剂C包括以下质量份数的组分:透明质酸钠0.03~0.07份、氢化卵磷脂0.6~1份、四氢甲基嘧啶羧酸0.05~0.15份、水解胶原0.3~0.7份、甜菜碱2~4份、二棕榈酰羟脯氨酸0.3~0.7份、牛油果树果脂6~10份、生育酚乙酸酯0.3~0.7份、活性成分A3 3~5份、活性成分B3 3~5份、活性成分C3 0.5~1.5份及红没药醇0.03~0.07份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011642603.3A CN112754963A (zh) | 2020-12-31 | 2020-12-31 | 紧致抗皱护肤品的使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011642603.3A CN112754963A (zh) | 2020-12-31 | 2020-12-31 | 紧致抗皱护肤品的使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112754963A true CN112754963A (zh) | 2021-05-07 |
Family
ID=75698730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011642603.3A Pending CN112754963A (zh) | 2020-12-31 | 2020-12-31 | 紧致抗皱护肤品的使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112754963A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115778862A (zh) * | 2022-12-03 | 2023-03-14 | 周嘉奇 | 一种隔离霜及其制备方法 |
CN116019733A (zh) * | 2022-12-26 | 2023-04-28 | 广东康容实业有限公司 | 一种超活南珠多肽母液修复抗衰组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090022599A (ko) * | 2007-08-31 | 2009-03-04 | (주)아모레퍼시픽 | 디팔미토일 하이드록시프롤린을 함유하는 튼살 완화용화장료 조성물 |
CN101744757A (zh) * | 2008-11-28 | 2010-06-23 | 高宝化妆品(中国)有限公司 | 含天然有机成分的无防腐保湿紧肤化妆品 |
CN109276518A (zh) * | 2018-11-20 | 2019-01-29 | 长沙黛西生物科技有限公司 | 不含乳化剂的修复抗衰面霜及其制备方法 |
CN109674703A (zh) * | 2019-01-29 | 2019-04-26 | 广州锦同生物科技有限公司 | 一种聚水保湿精华乳及其制备方法 |
CN110236964A (zh) * | 2019-05-24 | 2019-09-17 | 广州维真渼生物科技有限公司 | 肌活焕白霜及其制备方法 |
-
2020
- 2020-12-31 CN CN202011642603.3A patent/CN112754963A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090022599A (ko) * | 2007-08-31 | 2009-03-04 | (주)아모레퍼시픽 | 디팔미토일 하이드록시프롤린을 함유하는 튼살 완화용화장료 조성물 |
CN101744757A (zh) * | 2008-11-28 | 2010-06-23 | 高宝化妆品(中国)有限公司 | 含天然有机成分的无防腐保湿紧肤化妆品 |
CN109276518A (zh) * | 2018-11-20 | 2019-01-29 | 长沙黛西生物科技有限公司 | 不含乳化剂的修复抗衰面霜及其制备方法 |
CN109674703A (zh) * | 2019-01-29 | 2019-04-26 | 广州锦同生物科技有限公司 | 一种聚水保湿精华乳及其制备方法 |
CN110236964A (zh) * | 2019-05-24 | 2019-09-17 | 广州维真渼生物科技有限公司 | 肌活焕白霜及其制备方法 |
Non-Patent Citations (1)
Title |
---|
裘炳毅等: "《化妆品植物功效添加剂的研究与开发》", 中国轻工业出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115778862A (zh) * | 2022-12-03 | 2023-03-14 | 周嘉奇 | 一种隔离霜及其制备方法 |
CN116019733A (zh) * | 2022-12-26 | 2023-04-28 | 广东康容实业有限公司 | 一种超活南珠多肽母液修复抗衰组合物及其应用 |
CN116019733B (zh) * | 2022-12-26 | 2024-02-20 | 广东康容实业有限公司 | 一种超活南珠多肽母液修复抗衰组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11833242B2 (en) | Skin care formulations | |
US20210121379A1 (en) | Composition comprising at least two fatty acid esters of (poly)glycerol, and use thereof in cosmetics | |
CN112569133A (zh) | 紧致抗皱精华霜及其制备方法 | |
CN111166683A (zh) | 一种富勒烯抗衰抗氧化美容护肤化妆品及其制备方法 | |
CN113786376B (zh) | 一种具有去眼纹功效的眼霜组合物及其制备方法 | |
CN110897995A (zh) | 一种美白膏霜及其制备方法 | |
CN111686068A (zh) | 一种抗皱活肤霜及其制备方法 | |
CN112754963A (zh) | 紧致抗皱护肤品的使用方法 | |
CN112641670A (zh) | 保湿精华乳及其制备方法 | |
WO2020033450A1 (en) | Wrinkle reducing compositions and methods | |
CN111544348A (zh) | 一种祛皱霜及其制备方法 | |
US20030031688A1 (en) | Cosmetic composition with improved skin moisturizing properties | |
US20170209349A1 (en) | Topical skin care composition for night use | |
CN112516022B (zh) | 一种防晒露及其制备方法 | |
CN114159333B (zh) | 一种肌底液及其制备方法 | |
US20220378690A1 (en) | Compositions and methods for treating skin | |
JP7305161B2 (ja) | 皮膚化粧料 | |
CN112656728A (zh) | 抗敏舒缓液及其制备方法 | |
CN113730295A (zh) | 一种包含去皱紧致功效脂质纳米粒的精华乳组合物及其制备方法 | |
CN115813832B (zh) | 一种具有改善眼部轮廓的组合物、眼霜及其制备方法和应用 | |
AU2021105957A4 (en) | Body Lotion | |
CN114712277B (zh) | 一种保湿修复组合物和化妆品及制备方法 | |
CN115721596B (zh) | 一种修复抗皱美颜乳 | |
RU2678307C1 (ru) | Активная против акне добавка к парфюмерно-косметическим продуктам | |
CN115531249A (zh) | 一种具有控油功效的涂抹面膜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210507 |